MoneyWorks4Me

Wanbury informs about press release

23 Aug 2024 Evaluate
Wanbury has informed that the USFDA has issued an Establishment Inspection Report (EIR) for the Company’s manufacturing facility located at MIDC Industrial Area, Patalganga, Maharashtra, India and the inspection has now been successfully closed by the USFDA. USFDA has determined that the inspection classification of this facility is ‘No Action Indicated’ (NAI) with zero 483 observations. Based on this inspection, this facility is considered to be in an acceptable state of compliance with regards to current good manufacturing practice (CGMP).

The above information is a part of company’s filings submitted to BSE.
Peers
Company Name CMP
Sun Pharma. Inds. 1835.50
Dr. Reddys Labs. 1171.10
Cipla 1371.45
Lupin 2144.70
Zydus Lifesciences 1153.00
View more..